Get the Stockscreener App
3.05
1.61%
-0.05
After Hours:
3.17
0.12
+3.93%
Stereotaxis Inc stock is traded at $3.05, with a volume of 286.09K.
It is down -1.61% in the last 24 hours and up +8.54% over the past month.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to design and develop a next-generation magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.
See More
Previous Close:
$3.10
Open:
$3.11
24h Volume:
286.09K
Relative Volume:
0.50
Market Cap:
$277.77M
Revenue:
$25.14M
Net Income/Loss:
$-21.57M
P/E Ratio:
-11.30
EPS:
-0.27
Net Cash Flow:
$-12.23M
1W Performance:
+0.00%
1M Performance:
+8.54%
6M Performance:
+67.58%
1Y Performance:
+55.61%
1-Day Range:
$3.01
$3.11
1-Week Range:
$2.935
$3.204
52-Week Range:
$1.54
$3.59
Stereotaxis Inc Stock (STXS) Company Profile
Name
Stereotaxis Inc
Sector
Industry
Phone
314-678-6100
Address
4320 Forest Park Avenue, Suite 100, St. Louis, MO
Compare STXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STXS
Stereotaxis Inc
|
3.05 | 282.31M | 25.14M | -21.57M | -12.23M | -0.27 |
|
ISRG
Intuitive Surgical Inc
|
462.74 | 164.35B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
189.03 | 54.75B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
268.22 | 39.61B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ALC
Alcon Inc
|
75.76 | 37.31B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
279.39 | 19.77B | 2.96B | 487.70M | 344.00M | 6.6758 |
Stereotaxis Inc Stock (STXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-24 | Initiated | ROTH MKM | Buy |
| Jul-12-22 | Initiated | Aegis Capital | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Jan-05-22 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | Loop Capital | Buy |
| May-26-21 | Initiated | Piper Sandler | Overweight |
| Sep-08-20 | Initiated | Northland Capital | Outperform |
| Apr-09-20 | Initiated | Cowen | Outperform |
| Apr-07-20 | Initiated | Lake Street | Buy |
View All
Stereotaxis Inc Stock (STXS) Latest News
Visualizing Stereotaxis Inc. stock with heatmaps2025 Big Picture & AI Powered Trade Plan Recommendations - newser.com
Published on: 2025-10-21 19:22:31 - newser.com
Automated trading signals detected on Stereotaxis Inc.July 2025 EndofMonth & Accurate Entry and Exit Point Alerts - newser.com
Can Stereotaxis Inc. stock resist broad market declinesInflation Watch & Verified Technical Signals - newser.com
Can Stereotaxis Inc. stock retain market dominanceEarnings Beat & Weekly Watchlist of Top Performers - newser.com
Stereotaxis (NYSE: STXS) sets Q3 2025 results call and webcast information - Stock Titan
What valuation ratios show for Stereotaxis Inc. stockQuarterly Trade Review & Risk Controlled Daily Plans - newser.com
Stereotaxis Rolls Out Synchrony System in EU and Files for FDA Approval - sharewise.com
Can Stereotaxis Inc. stock test all time highsForecast Cut & Free Technical Pattern Based Buy Signals - newser.com
Will Stereotaxis Inc. stock outperform tech sector in 20252025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - newser.com
Is Stereotaxis Inc. stock attractive for income investorsJuly 2025 Short Interest & AI Based Buy and Sell Signals - newser.com
Is Stereotaxis Inc. stock a buy in volatile marketsJuly 2025 Intraday Action & Low Drawdown Trading Strategies - nchmf.gov.vn
Is Stereotaxis Inc. stock a buy on dips2025 Geopolitical Influence & Free Long-Term Investment Growth Plans - nchmf.gov.vn
Stereotaxis Synchrony System Gets European CE Mark; Applies for FDA 510(k) Certification - Diagnostic and Interventional Cardiology
Is Stereotaxis Inc. stock trading near support levelsMarket Activity Summary & Technical Pattern Based Buy Signals - newser.com
Can Stereotaxis Inc. stock continue upward trendMarket Risk Analysis & Growth Oriented Trade Recommendations - newser.com
Stereotaxis Earns EU Nod for Synchrony System, Submits to FDA - Medical Product Outsourcing
How Stereotaxis Inc. stock stacks up against competitors2025 Technical Patterns & Real-Time Buy Signal Notifications - newser.com
Stereotaxis teams with CardioFocus to develop robotic PFA system - MedTech Dive
Stereotaxis Obtains CE Mark in Europe, Files Application to FDA for Synchrony System - MarketScreener
Stereotaxis (STXS) Moves Forward with Synchrony System Approvals - GuruFocus
Stereotaxis obtains CE mark for Synchrony system, files FDA application By Investing.com - Investing.com Canada
Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs - GlobeNewswire
CE Mark & 510(k) Submission: Stereotaxis Launches Synchrony with 55” 4K Display and SynX Cloud - Stock Titan
Order flow analysis tools used on Stereotaxis Inc.Earnings Recap Summary & Daily Stock Momentum Reports - newser.com
STXS Partners With CardioFocus to Boost Robotic Pulsed Field Ablation - sharewise.com
Stereotaxis, CardioFocus Collab to Advance Robotic Pulsed Field Ablation - Medical Product Outsourcing
Stereotaxis (STXS) Partners with CardioFocus to Develop Robotic PFA Technology - GuruFocus
Stereotaxis and CardioFocus partner to develop robotic PFA technology - Investing.com
Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias - GlobeNewswire
Is Stereotaxis Inc. stock trading at attractive multiplesWeekly Profit Summary & Real-Time Buy Signal Alerts - newser.com
Stereotaxis Inc Stock Analysis and ForecastInstitutional Holding Changes & Free Explosive Portfolio Gains - earlytimes.in
Stereotaxis, Inc. Hits New 52-Week High of $3.58, Marking Key Milestone - Markets Mojo
Stereotaxis Inc Stock (STXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.77%
1.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):